Transgender women on oral HIV pre‐exposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender men
Eugenie Shieh(Johns Hopkins University), Craig W. Hendrix(Unknown)
Cited by 80
Related Papers
Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women
|New England Journal of Medicine|2012|3.3k
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
|New England Journal of Medicine|2021|891
Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women
|New England Journal of Medicine|2016|768
Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women
|Obstetrical & Gynecological Survey|2016|373
HIV Protective Efficacy and Correlates of Tenofovir Blood Concentrations in a Clinical Trial of PrEP for HIV Prevention
|JAIDS Journal of Acquired Immune Deficiency Syndromes|2014|368